Acalatinib drug information and correct usage

Acalabrutinib, as a highly selective Bruton's tyrosine kinase (BTK) inhibitor, has achieved remarkable results in the treatment of specific hematological tumors in recent years. This article aims to introduce in detail the drug information and correct use of acotinib to help patients better understand and use this drug.

1. Basic information about drugs

Acotinib, developed by AstraZeneca, is a new generation of highly selectiveBTK inhibitor. It is primarily indicated for the treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy, and is also recommended for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The specifications of acotinib are usually 100mg*60 tablets/box or 100mg*8 tablets*7 tablets/box, which facilitates long-term treatment for patients according to doctor’s instructions.

2. Correct usage

The correct use of acotinib is critical to ensuring its efficacy and safety. In general, the recommended dose for adult patients is 100 mg orally every 12 hours until disease progression or unacceptable toxicity. Patients should take medication at a fixed time every day, and try to keep the interval between two doses at 12 hours, such as once in the morning and once in the evening. Acotinib can be taken with water or food, but chewing or crushing the capsules is not recommended.

During the use of acotinib, patients should avoid taking it with foods that may affect drug metabolism, such as grapefruit or grapefruit juice, to avoid excessive drug concentration. In addition, if the patient forgets to take the medicine and the missed time is more than three hours, there is no need to take a missed dose, just take the normal dose at the next dose time.

It is worth noting that acotinib may cause some adverse reactions, such as headache, diarrhea, fatigue, muscle pain, etc. Patients should pay close attention to their own reactions during the medication. If they experience severe discomfort or suspected adverse reactions, they should seek medical treatment promptly and inform the doctor that they are using acotinib.

In summary, acotinib, as an innovative targeted therapy, provides a new treatment option for patients with specific hematological tumors. Patients should fully understand the drug information and correct usage before use, and use the drug rationally under the guidance of a doctor to ensure efficacy and safety. Currently, acotinib has both the original version and a more affordable generic version. Patients should choose according to their needs.